Boston, MA 05/22/2014 (wallstreetpr) – Dendreon Corporation (NASDAQ:DNDN) on May 20, 2014 announced that the drug called PROVENGE® (sipuleucel-T) can be very effective in improving the results on the patients of prostate cancer.
How Does The Drug Functions?
Dendreon Corporation (NASDAQ:DNDN), while presenting the data from IMPACT and ProACT studies, suggested that this drug can help the patients because it extracts the immune response which is directly proportionate to the benefit of overall survival.
Explaining the benefits of the drug, the Executive Vice President and Chief Medical Officer of the company, Dr. Andrew Sandler said that the data of the studies also expound the working of PROVENGE® in the treatment of metastatic castration-resistant prostate cancer. At the same time, he explained that the drug has a crucial role to play in the prescribing practices of oncologists as well as urologists.
2014 American Urological Association (AUA) Annual Meeting
The data from ProACT and IMPACT studies was represented in the podium presentation. Also, the data from PROCEED registry was presented, and this was included in general poster session during the aforementioned meeting held in Orlando, Florida from May 16-21, 2014.
Explanation From Dr. Andrew Sandler
Dr. Andrew Sandler, the Executive Vice President and Chief Medical Officer of Dendreon Corporation explained that the drug led to an elevated response from the immune system against the prostate-specific antigen (PSA), which indicated that there were higher benefits of the treatment.
Steps Taken By Dendreon Corporation
In this context, the Dendreon Corporation (NASDAQ:DNDN) will organise the registration activity of around 1500 patients in order to evaluate the potential signals of cerebrovascular events. This will be done as part of ongoing commitment of the company towards the patients as well as post marketing requirement. The company has already organised four random clinical trials of the drug in the patients suffering from prostate cancer and it was observed that there were cerebrovascular events in around 3.5% of these patients in PROVENGE group, in contrast with the 2.6% patients in control group.
